Ocufolin for Diabetic Retinopathy

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Diabetic Retinopathy+5 More
Ocufolin - DietarySupplement
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This trial will help researchers understand if these devices can be used to study different eye conditions and if Ocufolin can help improve vision.

Eligible Conditions
  • Diabetic Retinopathy
  • Presbyopia
  • Dementia
  • Multiple Sclerosis
  • Myopia
  • Dry Eye

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

5 Primary · 2 Secondary · Reporting Duration: up to 2 years

up to 2 years
Conjunctival blood flow velocity by functional slit-lamp (FSLB)
Conjunctival vasculature by functional slit-lamp (FSLB)
Corneal epithelial thickness
Retinal blood flow velocity by retinal function imager (RFI)
Retinal microstructure using OCT.
Retinal vasculature by optical coherence tomography angiography (OCTA)
Tear film thickness

Trial Safety

Trial Design

2 Treatment Groups

Observational Phase Group
1 of 2
Interventional Phase - Ocufolin Group
1 of 2
Active Control
Experimental Treatment

5000 Total Participants · 2 Treatment Groups

Primary Treatment: Ocufolin · No Placebo Group · N/A

Interventional Phase - Ocufolin Group
DietarySupplement
Experimental Group · 1 Intervention: Ocufolin · Intervention Types: DietarySupplement
Observational Phase GroupNoIntervention Group · 1 Intervention: Observational Phase Group · Intervention Types:
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Ocufolin
2017
N/A
~30

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: up to 2 years

Who is running the clinical trial?

University of MiamiLead Sponsor
787 Previous Clinical Trials
379,271 Total Patients Enrolled
1 Trials studying Diabetic Retinopathy
3,000 Patients Enrolled for Diabetic Retinopathy
Jianhua Wang, MD, PhDPrincipal InvestigatorBascom Palmer Eye Institute, University of Miami, Miami, FL
4 Previous Clinical Trials
161 Total Patients Enrolled

Eligibility Criteria

Age 18+ · All Participants · 4 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
You can keep the eye open for imaging.\n

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 13th, 2021

Last Reviewed: October 7th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.

Who else is applying?

What state do they live in?
Florida100.0%
How old are they?
18 - 65100.0%
What portion of applicants met pre-screening criteria?
Did not meet criteria100.0%